BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2008

View Archived Issues

Recent Bayer Schering Pharma patents disclose novel contraceptive agents

Read More

Chelsea granted U.K. approval for phase II droxidopa trial in fibromyalgia

Read More

Dendreon expects interim data analysis for IMPACT trial in October 2008

Read More

GP Pharm completes phase III Lutrate trial in advanced prostate cancer

Read More

HT-0712 primate study reveals significant enhancement of long-term memory

Read More

Janumet approved in the E.U. for type 2 diabetes

Read More

MethylGene and Celgene temporarily suspend new enrollment in MGCD-0103 trial

Read More

ProQuin XR achieves first E.U. marketing authorization in Sweden

Read More

Medicure able to fund operations until the end of 2008

Read More

Teva's acquisition of Bentley Pharmaceuticals completed

Read More

Health Canada grants approval to Santhera's Catena in Friedreich's ataxia

Read More

Novel radiotracer useful for imaging CB1 type receptors in schizophrenia

Read More

Combined statin and biphosphonate treatment shows promise in mouse model of human progeria

Read More

[11C]-CUMI-101, a novel radioligand with potential use in imaging 5-HT1A receptors

Read More

Vitespen fails to improve recurrence-free survival in high-risk renal cell carcinoma patients

Read More

FDA issues nonapprovable letter in response to NexMed's NDA for a topical treatment for ED

Read More

New agents for treating psychiatric disorders reported in recent AstraZeneca and Abbott patents

Read More

New oncolytic agents imparted in recent patents

Read More

Ipsen presents an update on the company's acquisition of Tercica

Read More

Roche to acquire Arius Research

Read More

Santarus and Depomed enter U.S. promotion agreement for Glumetza for type 2 diabetes

Read More

Emergent BioSolutions and University of Oxford form joint venture to develop MVA-85A

Read More

FDA grants regulatory clearance to Response Biomedical to market Ramp NT-proBNP test for HF

Read More

OncoVista Innovative initiates enrollment in phase I/II study of cordycepin

Read More

Talecris' aerosolized alpha1-antitrypsin designated orphan drug in Europe

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Brain and DNA

    Sex differences shape gene activity across the human brain

    BioWorld
    Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
  • Green arrow on blue abstract background

    Psychedelic space expanding on Trump’s EO

    BioWorld
    Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
  • Gilead Sciences patents new GTPase KRAS G12D inhibitors

    BioWorld Science
    Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing